DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

2,2-Bis(4-hydroxyphenyl)-1,1,1-trichloroethane

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CLD_CYP1A1_6hr	Liver	Human	1543	CYP1A1	Gain	0.06 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CCTE_Deisenroth_AIME_384WELL_LUC_Active	Mammary gland/breast	Human	2099	ESR1	Gain	0.72 μM
CCTE_Deisenroth_AIME_384WELL_LUC_Inactive	Mammary gland/breast	Human	2099	ESR1	Gain	0.4 μM
HCAN_AUR_hTPO	Kidney	Human	7173	TPO	Loss	1.16 μM
NVS_ADME_hCYP1A1		Human	1543	CYP1A1	Loss	10.0 μM
NVS_ADME_hCYP2C18		Human	1562	CYP2C18	Loss	0.67 μM
NVS_ADME_hCYP2C19		Human	1557	CYP2C19	Loss	1.03 μM
NVS_ADME_hCYP2C8		Human	1558	CYP2C8	Loss	1.06 μM
NVS_ADME_hCYP2C9		Human	1559	CYP2C9	Loss	2.07 μM
NVS_ADME_hCYP2J2		Human	1573	CYP2J2	Loss	2.95 μM
NVS_ADME_hCYP3A4		Human	1576	CYP3A4	Loss	7.75 μM
NVS_ADME_hCYP4F12		Human	66002	CYP4F12	Loss	0.61 μM
NVS_ADME_rCYP2A1		Rat	24894	Cyp2a1	Loss	1.29 μM
NVS_ADME_rCYP2A2		Rat	24895	Cyp2a2	Loss	1.01 μM
NVS_ADME_rCYP2B1		Rat	24300	Cyp2b1	Loss	9.18 μM
NVS_ADME_rCYP2C11		Rat	29277	Cyp2c11	Loss	0.15 μM
NVS_ADME_rCYP2C13		Rat	171521	Cyp2c13	Loss	0.88 μM
NVS_ADME_rCYP2C6		Rat	293989	Cyp2c6	Loss	2.19 μM
NVS_ADME_rCYP2D1		Rat	266684	Cyp2d1	Loss	3.43 μM
NVS_ADME_rCYP2D2		Rat	25053	Cyp2d2	Loss	3.61 μM
NVS_ADME_rCYP3A1		Rat	25642	Cyp3a23-3a1	Loss	3.45 μM
NVS_ADME_rCYP3A2		Rat	266682	Cyp3a2	Loss	3.43 μM
NVS_ENZ_hBACE		Human	23621	BACE1	Loss	4.96 μM
NVS_ENZ_hCASP5		Human	838	CASP5	Loss	11.26 μM
NVS_ENZ_hTrkA		Human	4914	NTRK1	Loss	12.94 μM
NVS_GPCR_g5HT4	Brain	Guinea pig	100135548	Htr4	Loss	2.7 μM
NVS_GPCR_h5HT5A		Human	3361	HTR5A	Loss	9.26 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	0.16 μM
NVS_GPCR_h5HT7		Human	3363	HTR7	Loss	9.31 μM
NVS_GPCR_hAdoRA1	Brain	Human	134	ADORA1	Loss	9.39 μM
NVS_GPCR_hAdra2C		Human	152	ADRA2C	Loss	9.18 μM
NVS_GPCR_hAdrb2		Human	154	ADRB2	Loss	8.91 μM
NVS_GPCR_hDRD1		Human	1812	DRD1	Loss	8.93 μM
NVS_GPCR_hM1		Human	1128	CHRM1	Loss	8.76 μM
NVS_GPCR_hM2		Human	1129	CHRM2	Loss	4.96 μM
NVS_GPCR_hM3		Human	1131	CHRM3	Loss	8.24 μM
NVS_GPCR_hM4		Human	1132	CHRM4	Loss	8.07 μM
NVS_GPCR_hOpiate_D1		Human	4985	OPRD1	Loss	5.12 μM
NVS_GPCR_hOpiate_mu		Human	4988	OPRM1	Loss	3.58 μM
NVS_IC_rCaDHPRCh_L	Brain	Rat	25398	Cacna1a	Loss	7.59 μM
NVS_MP_rPBR	Kidney	Rat	24230	Tspo	Loss	4.65 μM
NVS_NR_hAR		Human	367	AR	Loss	1.49 μM
NVS_NR_hCAR_Antagonist		Human	9970	NR1I3	Loss	0.02 μM
NVS_NR_hER		Human	2099	ESR1	Loss	0.04 μM
NVS_NR_hGR		Human	2908	NR3C1	Loss	0.99 μM
NVS_NR_hPR		Human	5241	PGR	Loss	8.86 μM
NVS_NR_mERa		Mouse	13982	Esr1	Loss	0.01 μM
NVS_NR_rAR	Prostate	Rat	24208	Ar	Loss	3.37 μM
NVS_TR_gDAT	Brain	Guinea pig	100714898	Slc6a3	Loss	1.88 μM
NVS_TR_hDAT		Human	6531	SLC6A3	Loss	0.44 μM
NVS_TR_hNET		Human	6530	SLC6A2	Loss	4.42 μM
NVS_TR_rVMAT2	Brain	Rat	25549	Slc18a2	Loss	7.63 μM
CCTE_Deisenroth_AIME_96WELL_LUC_Active	Mammary gland/breast	Human	2099	ESR1	Gain	0.14 μM
CCTE_Deisenroth_AIME_96WELL_LUC_Inactive	Mammary gland/breast	Human	2099	ESR1	Gain	0.12 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	0.1 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	0.5 μM
ATG_VDRE_CIS	Liver	Human	7421	VDR	Activatory	0.69 μM
BSK_3C_Thrombomodulin	Vascular	Human	7056	THBD	Inhibitory	6.1 μM
BSK_4H_MCP1	Vascular	Human	6347	CCL2	Inhibitory	14.65 μM
BSK_CASM3C_MCSF	Vascular	Human	1435	CSF1	Inhibitory	9.81 μM
BSK_CASM3C_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	11.29 μM
BSK_hDFCGF_CollagenIII	Skin	Human	1281	COL3A1	Inhibitory	11.69 μM
BSK_hDFCGF_EGFR	Skin	Human	1956	EGFR	Inhibitory	13.29 μM
BSK_hDFCGF_TIMP1	Skin	Human	7076	TIMP1	Inhibitory	14.46 μM
BSK_KF3CT_TGFb1	Skin	Human	7040	TGFB1	Inhibitory	9.66 μM
BSK_LPS_TNFa	Vascular	Human	7124	TNF	Inhibitory	4.9 μM
BSK_SAg_Eselectin	Vascular	Human	6401	SELE	Inhibitory	10.67 μM
BSK_SAg_IL8	Vascular	Human	3576	CXCL8	Inhibitory	11.76 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	2.98 μM
ATG_hERa_XSP1	Liver	Human	2099	ESR1	Gain	0.03 μM
ATG_hERa_XSP2	Liver	Human	2099	ESR1	Gain	0.14 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	8.35 μM
TOX21_ERa_BLA_Antagonist_ratio	Kidney	Human	2099	ESR1	Loss	0.81 μM
TOX21_ERa_LUC_VM7_Agonist	Breast	Human	2099	ESR1	Gain	0.06 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	12.15 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	5.34 μM
TOX21_CAR_LUC_Agonist	Liver	Human	9970	NR1I3	Gain	10.37 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2	Breast	Human	2099	ESR1	Loss	13.47 μM
TOX21_ERb_BLA_Antagonist_ratio	Kidney	Human	2100	ESR2	Loss	0.18 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	8.38 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	14.26 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	7.02 μM
TOX21_ERa_BLA_Antagonist_ratio	Kidney	Human	2099	ESR1	Loss	0.69 μM
TOX21_ERa_LUC_VM7_Agonist	Breast	Human	2099	ESR1	Gain	0.05 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	3.33 μM
TOX21_ERb_BLA_Antagonist_ratio	Kidney	Human	2100	ESR2	Loss	0.14 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	7.02 μM
TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780	Breast	Human	2099	ESR1	Gain	4.83 μM

ToxCast endpoints for intended target type: Molecular messenger

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CEETOX_H295R_11DCORT	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Activatory	2.05 μM
CEETOX_H295R_OHPREG	Adrenal gland	Human	5241	PGR	Activatory	0.3 μM
CEETOX_H295R_OHPROG	Adrenal gland	Human	5241	PGR	Inhibitory	10.0 μM
CEETOX_H295R_ANDR	Adrenal gland	Human	367	AR	Activatory	6.85 μM
CEETOX_H295R_CORTISOL	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	0.4 μM
CEETOX_H295R_DOC	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Activatory	0.21 μM
CEETOX_H295R_ESTRADIOL	Adrenal gland	Human	2099\|2100	ESR1\|ESR2	Inhibitory	10.0 μM
CEETOX_H295R_ESTRONE	Adrenal gland	Human	2099\|2100	ESR1\|ESR2	Inhibitory	10.14 μM
CEETOX_H295R_PROG	Adrenal gland	Human	5241	PGR	Inhibitory	0.85 μM
CEETOX_H295R_TESTO	Adrenal gland	Human	367	AR	Inhibitory	5.63 μM

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	4.44 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist	Bone	Human	367	AR	Gain	0.0 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist	Bone	Human	367	AR	Loss	3.37 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist	Bone	Human	367	AR	Gain	0.0 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	1.67 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist	Bone	Human	367	AR	Loss	1.27 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.08 μM
OT_ER_ERaERa_0480	Kidney	Human	2099	ESR1	Gain	0.37 μM
OT_ER_ERaERa_1440	Kidney	Human	2099	ESR1	Gain	0.26 μM
OT_ER_ERaERb_0480	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.13 μM
OT_ER_ERaERb_1440	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.06 μM
OT_ER_ERbERb_0480	Kidney	Human	2100	ESR2	Gain	0.03 μM
OT_ER_ERbERb_1440	Kidney	Human	2100	ESR2	Gain	0.03 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	0.01 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	0.23 μM
TOX21_ARE_BLA_Agonist_ratio	Liver	Human	4780	NFE2L2	Gain	12.0 μM
TOX21_PPARg_BLA_Antagonist_ratio	Kidney	Human	5468	PPARG	Loss	2.37 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	10.04 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.